Céline Marie Pauline Martin

Céline Marie Pauline Martin

Auto-generated profile, based on publicly available information

Céline Marie Pauline Martin

Toxalim (Research Center in Food Toxicology), INRAE UMR 1331, ENVT, INP-Purpan, Université de Toulouse, Toulouse, France

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2023 in Molecular Nutrition & Food Research
Verified
Journal Article
Open access
CRClémence Rives
Clémence Rives
CMCéline Marie Pauline Martin
Céline Marie Pauline Martin
LELauris Evariste
Lauris Evariste
APArnaud Polizzi
Arnaud Polizzi
MHMarine Huillet
Marine Huillet
AFAnne Fougerat
Anne Fougerat
Scope: Non‐alcoholic fatty liver disease (NAFLD) is a sexually dimorphic disease influenced by dietary factors. Here, the metabolic and hepatic effects of dietary amino acid (AA) source is assessed in Western diet (WD)‐induced NAFLD in male and female mice.Methods and results: The AA source is either casein or a free AA mixture mimicking the composition of casein. As expected, males fed a casein‐based WD display glucose intolerance, fasting hyperglycemia, and insulin‐resistance and develop NAFLD associated with changes in hepatic gene expression and microbiota dysbiosis. In contrast, males fed the AA‐based WD show no steatosis, a similar gene expression profile as males fed a control diet, and a distinct microbiota composition compared to males fed a casein‐based WD. Females are protected against WD‐induced liver damage, hepatic gene expression, and gut microbiota changes regardless of the AA source.Conclusions: Free dietary AA intake prevents the unhealthy metabolic outcomes of a WD preferentially in male mice.

31 January 2024 in Environmental Pollution
Verified
Journal Article
Closed access
NCNoemie Cresto
Noemie Cresto
MCMargot Courret
Margot Courret
AGAthénaïs Génin
Athénaïs Génin
CMCéline Marie Pauline Martin
Céline Marie Pauline Martin
JBJulie Bourret
Julie Bourret
NMNicola Marchi
Nicola Marchi

27 April 2026 in EMBO Reports
Verified
Journal Article
Open access
PDF file
JBJustine Bruse
Justine Bruse
CMClothilde Marbach
Clothilde Marbach
APArnaud Polizzi
Arnaud Polizzi
TLTatiana Landre
Tatiana Landre
JSJuliette Salvi
Juliette Salvi
AFAnne Fougerat
Anne Fougerat
Fasting initiates a coordinated metabolic response to preserve energy balance. As glycogen stores are depleted, the body transitions to mobilizing fatty acids from adipose tissue and generating ketone bodies in the liver to sustain the function of vital organs. A network of hormonal signals and transcriptional programs coordinate these adaptations. Among these, the hepatokine fibroblast growth factor 21 (FGF21) is strongly upregulated during fasting and has been proposed as a key mediator of the fasting response. To investigate the physiological functions of FGF21, we study mice with hepatocyte-specific deletion of Fgf21 . Although the liver is the primary source of circulating FGF21 during fasting, its absence in hepatocytes does not alter typical fasting-induced gene expression or key metabolic pathways such as hepatic gluconeogenesis, adipose tissue lipolysis, or ketone production. Instead, we uncover a distinct role for FGF21 in promoting protein appetite following a fast. These findings challenge the conventional view of hepatocyte-produced FGF21 as a fasting-acting hormone and reveal a more specialized function in guiding nutrient selection after energy depletion.

23 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JPJean Personnaz
Jean Personnaz
LCLisa Cannizzo
Lisa Cannizzo
CMCéline Marie Pauline Martin
Céline Marie Pauline Martin
ADAurore Desquesnes
Aurore Desquesnes
MSManon Sotin
Manon Sotin
LKLéon Kautz
Léon Kautz
Metabolic dysfunction-associated steatotic liver disease (MASLD) begins with simple steatosis, which can progress to hepatocellular carcinoma (HCC). The pathogenesis of MASLD alters the secretion of hepatokines such as fibrinogen-like 1 (FGL1), a candidate mediator of liver steatosis and hyperglycemia. To investigate the contribution of FGL1 to liver diseases, we compared wild-type mice to mice with hepatocyte-specific deletion of Fgl1 subjected to a steatosis or HCC experimental protocol. We found that mice deficient for Fgl1 in hepatocytes showed higher levels of plasma glucose, pronounced metabolic alterations and liver injury when fed a western diet compared to their wild-type counterparts. However, both genotypes exhibited a similar lipid deposition in the liver. Similarly, wild type and Fgl1 -deficient mice displayed comparable liver alterations during HCC progression. We observed that FGL1 expression was repressed during MASLD progression in mice and human concomitantly with the severity of liver injury. Altogether, these findings suggest that FGL1 is not a major contributor to the pathogenesis of MASLD and HCC.